Skip to main content

Table 1 Eligible/noneligible patients at prescreening and numbers screened and enrolled for the five core sites

From: Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience

Study site

Total pool

Noneligible

Eligible

Screened

Enrolled

n

(% of total pool)

Mean age (years)

Male, n

(% of noneligible)

Female, n (% of noneligible)

n

(% of total pool)

Mean age (years)

Male, n (% of eligible)

Female, n (% of eligible)

n

(% of eligible)

n

(% of eligible)

Essen

109

24 (22.0)

71

7 (29.2)

17 (70.8)

85 (78.0)

   

5 (5.9)

2 (2.4)

Glostrup

221

160 (72.4)

67

54 (33.8)

106 (66.2)

61 (27.6)

64

29 (47.5)

32 (52.5)

12 (19.7)

6 (9.8)

London

161

82 (50.9)

67

29 (35.4)

53 (64.6)

79 (49.1)

60

30 (38.0)

49 (62.0)

1 (1.3)

0

Rome

130

46 (35.4)

69

14 (30.4)

32 (69.6)

84 (64.6)

63

28 (33.3)

56 (66.7)

28 (33.3)

15 (17.9)

Zurich

15

2 (11.1)

62

0

2 (100.0)

13 (88.9)

58

4 (30.8)

9 (69.2)

10 (62.5)

3 (18.8)

TOTAL

636

314 (49.1)

   

322 (50.6)

   

56 (17.4)

26 (8.1)